EIF2AK3 and acute myeloid leukemia: We identified signalling pathways downstream of CaSR involving pERK, β-catenin and c-MYC, as well as filamin A for AML progression and LSC renewal, while providing a strategy for targeting CaSR or possibly FLNA in conjunction with standard chemotherapy.